Notably, in contrast to the FACT-G and FACT-L scores, an increasing trend in the TOI was observed, ranging from 33.8 at baseline to 42.0 at weeks 5–45.0 at week 8, although this trend was not significant ( Fig. 1 ).
← all excerpts
Phase II Clinical Trial of Gefitinib for the Treatment of Chemonaïve Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status.
1
—
—